• Mashup Score: 0

    Lisa Roth, MD, Weill Cornell Medicine, New York, NY, discusses a multicenter retrospective study of pediatric patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) who received brentuximab vedotin (BV) as maintenance therapy following autologous stem cell transplantation (autoSCT). Dr Roth shares that the treatment was well tolerated and safe, suggesting that this agent may be a promising option for pediatric patients. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Tweet Tweets with this article
    • We had a lovely interview recently with Lisa Roth (@WeillCornell) who spoke on a retrospective study evaluating the use of brentuximab vedotin after autoSCT in pediatric patients with R/R #Hodgkin lymphoma. 🎥: https://t.co/9MdT9IWFC2 #17ICML #LymSM #BMTsm #ImmunoOnc

  • Mashup Score: 2

    Currently, there is no standard of care for older patients who develop classical Hodgkin lymphoma (cHL), and conventional chemotherapy is associated with several toxicities. In this video, Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, Peter MacCallum Cancer Centre, Melbourne, Australia, shares some insights into a study evaluating the safety and efficacy of pembrolizumab monotherapy in patients with cHL ineligible for frontline ABVD. Prof. Dickinson discusses the inclusion criteria for this trial, and further summarizes the results, including the progression-free and overall survival (PFS; OS) rates observed. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Tweet Tweets with this article
    • #17ICML | @mike_dickinson1 shares some insights into a study evaluating the safety & efficacy of pembrolizumab monotherapy in older patients with #Hodgkin lymphoma ineligible for frontline ABVD: 👉 https://t.co/eReOEiMXxJ 👈 @icmlugano #LymSM #ImmunoOnc

  • Mashup Score: 0

    Lara C. Pullen, PhD, is a freelance medical writer in Chicago. To achieve optimal disease control in patients with early-stage favorable nodular lymphocyte-​predominant Hodgkin lymphoma (NLPHL), consolidation radiotherapy (RT) appears necessary after two cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemot herapy, irrespective of the interim positron emission tomography (iPET) result, concluded Dennis Eichenauer, MD, of the University of Cologne in Germany, and colleagues in a

    Tweet Tweets with this article
    • To achieve optimal disease control in patients with early-stage favorable nodular lymphocyte-​predominant #Hodgkin #lymphoma, consolidation radiotherapy appears to be necessary after two cycles of ABVD #chemotherapy, regardless of the iPET result https://t.co/uMSK2EbUuf